ForGrowth NAP B.V.

ForGrowth NAP B.V. sells 74,910 shares (74.9K) at $25.98 avg, -$1.9M, amid unprofitable pharma startup with -86.3% revenue decline

ForGrowth NAP B.V., a 10% owner of NewAmsterdam Pharma (NAMS), executed two separate sales totaling 74,910 shares for $1,945,918.39 on 2024-12-26 and 2024-12-27 at an average price of $25.98. The company remains unprofitable with net income of $-16,647,000.00 and has experienced severe revenue contraction of -86.3% year-over-year, raising fundamental questions about the sustainability of the business. Despite NAMS stock appreciating 29.0% over the past 30 days and 48.1% over 90 days, ForGrowth has initiated its fifth distinct sale at this ticker in six trading days (2024-12-19 through 2024-12-26), reducing its holding from 10.76M to 10.69M shares. The rapid cadence of insider selling during a sustained rally in a structurally challenged business deserves investor scrutiny of the company's forward guidance and the reasons motivating the 10% stakeholder's sequential liquidation pattern.

10% owner ForGrowth NAP B.V. sold 91,068 shares for $2,329,520.00 across 4 transactions Dec 20–24

ForGrowth NAP B.V., a 10% shareholder in NewAmsterdam Pharma, executed 4 separate sales totaling 91,068 shares for $2,329,520.00 at an average price of $25.58 between December 20–24, 2024, reducing its stake by 0.8% to 10,760,928 shares. The sales occurred during a period of strong upward price momentum—the stock has gained 25.9% over 30 days and 61.6% over 90 days, with the current price of $26.23 only 1.4% below the 52-week high of $26.61. The company faces significant operational headwinds: annual revenue declined 86.3% year-over-year, the latest quarter showed negative net income of $-16,647,000.00 against minimal revenue of $29,111,000.00, and the company was unprofitable over its most recent full fiscal year. The timing and volume of these sales during a period of elevated valuation and deteriorating fundamentals warrant investor attention.

ForGrowth NAP B.V. sold 157,234 shares ($4.1M) across 3 transactions at blended avg $25.86; 10% owner now holds 10,851,996 shares

ForGrowth NAP B.V., a 10% shareholder in NewAmsterdam Pharma, executed 3 separate sales totaling 157,234 shares for $4,066,713.80 at transaction prices between $25.45 and $26.55 on 2024-12-18 and 2024-12-19. The stake reduction of 1.4% against pre-transaction holdings comes as the stock trades at $25.50 (current), with a 52-week high of $26.61, suggesting the insider sold near recent peaks. The company faces fundamental headwinds: annual revenue contracted 86.3% year-over-year, net income stands at -$16.6M on quarterly revenue of $29.1M, and the firm has been unprofitable over its most recent full fiscal year. These sales by a major institutional holder occur in the context of deteriorating operational metrics and represent the insider's most recent activity at this ticker following a pattern of 5 prior trades within the last several days (2024-12-16 through 2024-12-20), all sells.

ForGrowth NAP B.V. (10% owner) sold 115,480 shares of NAMS for $2,996,156.01 in three transactions at $25.00–$26.45 on Dec 16–17, 2024.

ForGrowth NAP B.V., a 10% holder of NewAmsterdam Pharma, executed three separate sales totaling 115,480 shares for $2,996,156.01 over two trading days at prices ranging from $25.00 to $26.45, reducing its stake from 11,124,710 to 11,009,230 shares (-1.0%). The sales occurred near the 52-week high of $26.61 and the stock has risen 5.0% over the past 30 days and 61.2% over 90 days, but the company remains unprofitable with annual revenue declining 86.3% and a net loss of $16,647,000.00 in the latest quarter. The timing of this sale at elevated valuations following a sharp 90-day rally, combined with deteriorating fundamentals and ongoing losses, warrants attention to the holder's conviction regarding the company's trajectory.

ForGrowth NAP B.V. (10% owner) sells 191,762 shares across 3 transactions for $4,859,875.24 at NAMS

ForGrowth NAP B.V., a 10% owner, executed 3 separate sales totaling 191,762 shares for $4,859,875.24 between December 10–13, 2024, reducing holdings from 11,316,472 shares to 11,124,710 shares (a -1.7% reduction). The blended average price of $25.34 sits above the current price of $24.71 and near the 52-week high of $26.19. The underlying company is unprofitable (net income of $-16,647,000.00 in the latest quarter) with severe revenue contraction (-86.3% annual growth). The timing of this sale relative to fundamentals warrants scrutiny: a major shareholder is liquidating a modest tranche while the stock remains elevated in its range, amid deteriorating business performance. Prior trades at NAMS are too recent to show measurable outcomes, limiting direct comparison of this insider's timing accuracy at this specific ticker.

ForGrowth NAP B.V. (10% owner) sells 462,288 shares over 2 days for $11,740,617.82, reducing stake to 11,316,472 shares

A 10% shareholder liquidated 462,288 shares (462.3K shares) across five separate transactions on 2024-12-10 and 2024-12-11, realizing $11,740,617.82 at prices ranging from $25.22 to $27.11 and a blended average of $25.40. The sale reduced ForGrowth NAP B.V.'s stake by 3.9%, from 11,778,760 shares to 11,316,472 shares, while the stock traded near its 52-week high of $26.19 and up 57.2% over 90 days. The sale occurs against a backdrop of severe financial stress: the company generated negative $16,647,000 in net income on quarterly revenue of $29,111,000, and experienced an 86.3% annual revenue decline year-over-year. The multi-transaction structure and substantial dollar volume ($11.7M) indicate a deliberate execution rather than incidental trading, warranting review of ForGrowth NAP B.V.'s strategic position and any concurrent disclosures regarding the divestiture rationale.

10% owner ForGrowth NAP sold 41,803 shares (41.8K) for $1,047,876.21 in 2 transactions at $25.02–$25.08

ForGrowth NAP B.V., a 10% owner of NewAmsterdam Pharma Co, executed 2 separate sales totaling 41,803 shares for $1,047,876.21 ($1.0M) on 2024-11-15 and 2024-11-18 at blended average price $25.07. The sales reduced holdings from 11,820,563 to 11,778,760 shares, a -0.4% reduction. The stock trades at $23.68 currently, 5.2% below the 52-week high of $24.97, and has gained 23.0% over 30 days and 45.5% over 90 days. NAMS is an unprofitable company with full-year net income of $-16,647,000 and annual revenue decline of -86.3%, suggesting fundamental distress that constrains the significance of this routine divestiture by a major shareholder.